P14-4 A case of renal pelvic cancer treated with afatinib after reconsidering pathological diagnosis based on findings of CGP

Takumi Fujiwara,Yoshinaga Okugawa,Takahito Kitajima,Haruko Saiki,Yasutaka Tono,Hajime Fujimoto,Kanako Saito,Ryotaro Hashizume,Hiroshi Imai,Toshiro Mizuno,Tetsu Kobayashi

ANNALS OF ONCOLOGY（2022）

引用 0|浏览8

暂无评分

摘要

One of the purposes for conducting comprehensive genome profile (CGP) is treatment optimization. CGP might provide a new treatment option and via reconsidering the diagnosis. We experienced a case of renal pelvic cancer (RPC) whose diagnosis was changed based on findings of CGP test.

查看译文

关键词

renal pelvic cancer,afatinib,pathological diagnosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要